Genprex Inc. (GNPX)

Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.

GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead drug candidate REQORSA Immunogene therapy, in combina...

Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Drug Administration (FDA) has granted Fast Track Desi...

Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.

Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combined with Tagrisso in late-stage non-small cell lung...

Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combination with Tagrisso in late-stage non-small cell l...

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the company announced. Investors liked what they saw, as sha...

Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functions as a novel tumor suppressor for glioblastoma. G...